AVITA Medical provided unaudited preliminary financial results for the fourth quarter and fiscal year 2025, showcasing significant growth.
The company secured a new credit facility with Perceptive Advisors to refinance existing debt and bolster its long-term growth prospects.
The revenue outlook for 2026 projects a robust 12% to 19% expansion compared to 2025, indicating a promising growth trajectory.
Financial Results
AVITA Medical reported total net revenues of $17.6 million in Q4 2025 and $71.6 million for the full year, marking an 11% increase over 2024, driven by operational efficiencies and increased product demand.
Debt Refinancing
The company successfully secured a new credit facility of up to $60 million with Perceptive Advisors, enhancing its capital structure and providing greater financial flexibility for strategic investments and operational enhancements.
Revenue Outlook
AVITA Medical anticipates full-year 2026 revenue in the range of $80 to $85 million, reflecting a growth rate of 12% to 19% from 2025, supported by strong market demand for its products and ongoing operational improvements.
Clinical Studies
Key clinical trials, including the Cohealyx-I study and the PermeaDerm-I study, achieved significant milestones in December 2025, with full enrollment and substantial progress, setting the stage for valuable data releases later in 2026.
- Throughout 2025, AVITA Medical prioritized stabilizing revenues, advancing clinical programs, and strengthening its financial position, laying the foundation for sustainable growth and operational excellence.
- The successful execution of debt refinancing and the optimistic revenue forecast for 2026 demonstrate the company's proactive approach to enhancing financial stability, fueling growth opportunities, and driving shareholder value in the upcoming year.
- The notable progress in clinical studies and key financial achievements in 2025 not only underscore AVITA Medical's commitment to innovation and operational efficiency but also signal a positive growth trajectory and improved profitability prospects for the future.
AVITA Medical's strategic focus on financial stability, debt optimization, and revenue expansion in 2025 sets a robust foundation for accelerated growth in 2026, aligning with the company's strategic objectives and positioning it for sustained market outperformance.